Skip to main content
. 2018 Sep 10;14(2):40–49. doi: 10.17925/EE.2018.14.2.40

Figure 2: Risk reduction of heart failure over time for empagliflozin versus placebo in the EMPA-REG OUTCOME study.

Figure 2:

Reproduced with permission from Fitchett et al., 201836 CI = confidence interval; EMPA-REG OUTCOME = empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes study; HR = hazard ratio; No. = number.